New Advances in Chemical Research, May 2021. In heterogeneous catalysis, the catalyst is in a different phase from the reactants. Application of 2213-63-0, We’ll be discussing some of the latest developments in chemical about CAS: 2213-63-0, name is 2,3-Dichloroquinoxaline. In an article，Which mentioned a new discovery about 2213-63-0
[From equivalent EP1661889A1] The present invention relates to a compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medical use thereof (the symbols in the formula are as described in the specification). The compound represented by formula (I) has chemokine receptor (especially in CCR4 and/or CCR5) antagonistic activity. Therefore it is useful for prevention and/or treatment of a chemokine receptor-mediated disease such as inflammatory and/or allergic diseases [systemic inflammatory response syndrome (SIRS), anaphylaxis, anaphylactoid reaction, allergic angiitis, transplant rejection reaction, hepatitis, nephritis, nephropathy, pancreatitis, rhinitis, arthritis, inflammatory ocular disease, inflammatory bowel disease, disease in cerebro and/or circulatory system, respiratory disease, dermatosis, autoimmune disease, and the like], infection [viral disease (human immunodeficiency virus infection, acquired immunodeficiency syndrome, SARS, etc.), and the like], and the like.
Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Application of 2213-63-0. In my other articles, you can also check out more blogs about 2213-63-0
Reference：
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N1190 | ChemSpider